Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229956 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL24878606 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL667613 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL29195406 | 1.00 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL13715722 | 0.96 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL3915198 | 0.96 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL6928627 | 0.95 | P2RY6 (0.40) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL6518721 | 0.94 | TYMP (0.35) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL16214972 | 0.94 | TYMP (0.35) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL668064 | 0.94 | TYMP (0.35) | TYMPP2RY6P2RY14NT5EP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | NSUN2, RNGTT, NSUN3 | TYMP 497/4885P2RY6 1688/4885P2RY14 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.